Current Study Opportunities at The CRC

Study #1: Clinical research study for adults with chronic cough 18-80 years of age will study an investigational inhaled medication taken daily.

Brief description of study

To qualify for this research study, you must have refractory or unexplained chronic cough for at least one year or longer. The study requires 7 on site visits and 2 phone calls over approximately 13 weeks. Morning appointments are required. Participation in this research study includes a chance of placebo. Must be a non-smoker with a ≤20 pack-year smoking history without COPD. Other criteria may apply.

Compensation for participation may be provided for those who qualify. Please fill out the Volunteer Questionnaire or call 314-514-850

Study #2: Asthma Research Study for adults 18 years of age or older who have had asthma diagnosed by a physician for at least 6 months and with acute airway obstruction induced by repeated mannitol challenges

Brief description of study

This investigational research study is enrolling participants with asthma who are using as-needed SABA (for example, Ventolin, ProAir, albuterol, etc.) as their only asthma treatment for at least 4 weeks. Participants must be non-smokers without significant smoke history and cannot be receiving allergen-specific immunotherapy (allergy shots). The study requires 3 on site visits and 1 phone call over approximately 4-5 weeks.

Compensation for participation may be provided for those who qualify. Please fill out the Volunteer Questionnaire or call 314-514-8509

Study #3: Asthma Research Study for adults 18 years of age or older who have had asthma diagnosed by a physician for at least 12 months and who have been treating with no daily inhaled maintenance therapy or with daily low-dose ICS or ICS/LABA

Brief description of study

This investigational research study is enrolling participants with asthma who are using as-needed SABA (for example, Ventolin, ProAir, albuterol, etc.) as their only asthma treatment or who have been on a stable low dose of ICS (for example, Pulmicort, Flovent, etc.) for at least 3 months or a stable low dose of ICS/LABA (for example, Symbicort, Advair, etc.) for at least 6 months. Participants must be non-smokers without a significant smoking history. The study requires 5 on site visits and 1 follow up phone call over approximately 14-15 weeks.

Compensation for participation may be provided for those who qualify. Please fill out the Volunteer Questionnaire or call 314-514-8509

Study #4: Research Study of an investigational oral medication taken twice daily for adults with diagnosed Refractory Chronic Cough including Unexplained Chronic Cough

Brief description of study

This clinical research study requires 20 on site visits and 2 phone calls over approximately 65 weeks. Participants must have persistent cough for at least one year and a diagnosis of Chronic Refractory Cough with insufficient improvement after treatment for underlying conditions or for which no underlying conditions have been determined despite adequate investigation with diagnostic tests and trials of therapy. Participants are required to wear a 24-hour cough monitor multiple times throughout the duration of the research study.

Compensation for participation may be provided for those who qualify. Please fill out the Volunteer Questionnaire or call 314-514-8509

Study #5: Research study for Chronic Spontaneous Urticaria (Hives) testing the efficacy and safety of an investigational daily oral medication versus placebo

Brief description of study

This research study requires 12 visits over approximately 48 weeks. Participants must be between 18-65 years of age and have been diagnosed with chronic spontaneous hives for at least the past 3 months. Hives must be inadequately controlled despite treatment with second-generation H-1 antihistamines (for example: Claritin, Allegra, Zyrtec, etc.). Participants cannot be on current treatment with biologics (for example: omalizumab, dupilumab, etc.) or have a clearly defined predominant or sole trigger for their hives. After the first 12 weeks of placebo-controlled treatment, there is an open-label extended period of treatment for 24 weeks where all participants are assigned one of three doses of the investigational drug.

Compensation for participation may be provided for those who qualify. Please fill out the Volunteer Questionnaire or call 314-514-8509Study

#6: Research study testing the efficacy and safety of an investigational drug versus placebo in participants with chronic rhinosinusitis without nasal polyps (CRSsNP)

Brief description of study

This investigational research study has 9 on site visits over about 8 months. Subjects must be between 18-75 years old and have a history of CRSsNP with ongoing symptoms of nasal congestion. Participants must have a history of previous sinonasal surgery for CRS and/or treatment with antibiotics or systemic corticosteroids for CRS within the past year. This study requires participants to remain on background therapy of stable dose mometasone furoate nasal spray from at least 4 weeks before visit 2 throughout the study and participants will undergo sinus CT scan and nasal endoscopy among other procedures.

Compensation for participation may be provided for those who qualify. Please fill out the Volunteer Questionnaire or call 314-514-8509

Study #7: COPD Research Study comparing investigational inhaled triple therapy to investigational inhaled double therapy.

Brief description of study

This investigational research study requires 12 visits over approximately 55 weeks. A chest x-ray is required within 6 months of or at screening. Participants must be at least 40 years of age with physician diagnosed COPD and be treating with a daily inhaled maintenance therapy with a stable dose for at least 3 months. Participants must have experienced 1-2 COPD flare(s) requiring treatment with oral steroids or antibiotics or have been hospitalized within the past 12 months. For more information about this research study, you may wish to view the video below.

Compensation for participation may be provided for those who qualify. Please fill out the Volunteer Questionnaire or call 314-514-8509.

Study #8: Research study for adults with chronic spontaneous urticaria (hives). Evaluating the effects of an investigational daily oral medication versus placebo.

Brief description of study

This clinical research study requires 5 visits over approximately 12-14 weeks. Must be at least 18 years of age or older and have a diagnosis of CSU for at least 6 months or longer. Morning appointments required. 

Compensation for participation may be provided to those who qualify. Please fill out the Volunteer Questionnaire or call 314-514-8509 for more details.

Study #9: A clinical research study for adults 18 years of age or older who have been diagnosed with asthma and have filled 2 or more prescriptions for their rescue inhaler (for example, Ventolin, ProAir, albuterol, etc.) within the past 12 months

Brief description of study

This investigational research study has 3 on site visits and 2 televisits (phone calls) over approximately 14-15 weeks. We are doing this research study to learn more about how AIRSUPRA® decreases inflammation, asthma symptoms, and rescue therapy use compared to albuterol alone in participants with mild asthma, and also to better understand asthma and associated health problems. This study will require FeNO testing, home spirometry testing and a daily eDiary in addition to other procedures.

Compensation for participation may be provided for those who qualify. Please fill out the Volunteer Questionnaire or call 314-514-8509

Study #10: A Phase 1B/2A, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of an investigational monoclonal antibody in Adult Patients with Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Treatment With, or Who Cannot Tolerate Omalizumab

Brief description of study

This investigational research study is enrolling participants 18 years of age or older who have a diagnosis for at least 6 months of CSU and have the presence of itch and hives for at least 8 consecutive weeks prior to screening despite current use of H1-antihistamines (for example, Zyrtec, Claritin, Allegra, Clarinex, Xyzal, etc.) and who have the presence of itch and hives for at least 8 consecutive weeks at any time prior to screening despite treatment with omalizumab (Xolair) or intolerance to omalizumab. This research study takes approximately 40-52 weeks to complete, with the number and frequency of visits varying depending on which cohort of the study into which a participant is placed. Most cohorts include the possibility of placebo.

Compensation for participation may be provided to those who qualify. Please fill out the Volunteer Questionnaire or call 314-514-8509 for more details.